Staff Profile

I have been working at the Newcastle Clinical Trials Unit (NCTU) since June 2017 and am current a Senior Trial Manager working on a portfolio of research studies.

I have 15 years of experience of working in research; as a laboratory based scientist and in trial management roles. I have worked in both academic and health care settings on a variety of research projects including translational research and first-in-human, CTIMP, ATMP and surgical clinical trials.  . 

Qualifications

• PhD, Institute for Cell and Molecular Biosciences, Newcastle University
• MRes, Medical and Molecular Biosciences, Newcastle University
• BSc (Hons) Medical Microbiology and Immunology, Newcastle University

Relevant Previous Positions

• Trial Manager, June 2017 - Oct 2021 (Newcastle Clinical Trials Unit, Newcastle University)
• Oncology Trials Coordinator, Aug 2014 - Jun 2017 (Sir Bobby Robson Cancer Clinical Trials Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust)
• Research Associate, Feb 2012 - Jul 2014 (Northern Institute for Cancer Research, Newcastle University)
• Research Technician, Feb 2011 - Feb 2012 (Northern Institute for Cancer Research, Newcastle University)

Memberships

• UK Trial Managers Network

• Articles

  • Morton M, Wilson N, Homer TM, Simms L, Steel A, Maier R, Wason J, Ternent L, Abouhajar A, Allen M, Joyce R, Hildreth V, Lakey R, Cherlin S, Walker A, Devereux G, Chalmers JD, Hill AT, Haworth C, Hurst JR, De Soyza A. Dual bronchodilators in Bronchiectasis study (DIBS): protocol for a pragmatic, multicentre, placebo-controlled, three-arm, double-blinded, randomised controlled trial studying bronchodilators in preventing exacerbations of bronchiectasis. BMJ Open 2023, 13(8), e071906.
  • Pratt AG, Siebert S, Cole M, Stocken DD, Yap C, Kelly S, Shaikh M, Cranston S, Morton M, Walker J, Frame S, Ng WF, Buckley CD, McInnes IB, Filer A, Isaacs JD. Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. The Lancet Rheumatology 2021, 3(5), e337-e346.
  • Siebert S, Pratt AG, Stocken DD, Morton M, Cranston A, Cole M, Frame S, Buckley CD, Ng W-F, Filer A, McInnes IB, Isaacs JD. Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial. Medicine 2020, 99(26), e20458.
  • Clark E, Morton M, Sharma S, Fisher H, Howel D, Walker J, Wood R, Hancock H, Maier R, Marshall J, Bahl A, Crabb S, Jain S, Pedley I, Jones R, Staffurth J, Heer R. Prostate cancer androgen receptor splice variant 7 biomarker study - A multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open 2019, 9(12), e034708.
  • de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discovery 2017, 7(6), 620-629.
  • Kos I, Patterson MJ, Znaidi S, Kaloriti D, da Silva Dantas A, Herrero-de-Dios C, d'Enfert C, Brown AJP, Quinn J. Mechanisms underlying the delayed activation of the Cap1 transcription factor in Candida albicans following combinatorial oxidative and cationic stress important for phagocytic potency. mBio 2016, 7(2), e00331-16.
  • Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patternson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia. Oncotarget 2015, 6(41), 43978-43991.
  • Middleton FK, Patterson MJ, Elstob CJ, Fordham S, Herriott A, Wade MA, McCormick A, Edmondson R, May FEB, Allan JM, Pollard JR, Curtin NJ. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget 2015, 6(32), 32396-32409.
  • Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. British Journal of Cancer 2014, 110, 1977-1984.
  • Kaloriti D, Jacobsen M, Yin ZK, Patterson M, Tillmann A, Smith DA, Cook E, You T, Grimm MJ, Bohovych I, Grebogi C, Segal BH, Gow NAR, Haynes K, Quinn J, Brown AJP. Mechanisms Underlying the Exquisite Sensitivity of Candida albicans to Combinatorial Cationic and Oxidative Stress That Enhances the Potent Fungicidal Activity of Phagocytes. MBIO 2014, 5(4), e01334-14.
  • Patterson MJ, Sutton RJ, Forrest I, Sharrock R, Lane M, Kaufmann A, O'Donnell R, Edmondson R, Wilson BT, Curtin N. Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples. British Journal of Cancer 2014, 111(1), 94-100.
  • Patterson M, McKenzie C, Smith D, da Silva Dantas A, Sherston S, Veal EA, Morgan B, MacCallum D, Erwig LP, Quinn J. Ybp1 and Gpx3 Signaling in Candida albicans Govern Hydrogen Peroxide-Induced Oxidation of the Cap1 Transcription Factor and Macrophage Escape. Antioxidants & Redox Signaling 2013, 19(18), 2244-2260.
  • Gaymes TJ, Mohamedali AM, Patterson M, Matto N, Smith A, Kulasekararaj A, Chelliah R, Curtin N, Farzaneh F, Shall S, Mufti GJ. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica 2013, 98(9), 1397-1406.
  • da Silva Dantas A, Patterson MJ, Smith DA, MacCallum DM, Erwig LP, Morgan BA, Quinn J. Thioredoxin regulates multiple hydrogen peroxide-induced signaling pathways in Candida albicans. Molecular and Cellular Biology 2010, 30(19), 4550-4563.
  • Cheetham J, Smith DA, da Silva Dantas A, Doris KS, Patterson MJ, Bruce CR, Quinn J. A single MAPKKK regulates the Hog1 MAPK pathway in the pathogenic fungus Candida albicans. Molecular Biology of the Cell 2007, 18(11), 4603-4614.

• Book Chapter

  • Patterson MJ, Drew Y, Curtin NJ. PARP. In: Cancer Therapeutic Targets. New York: Springer, 2017, pp.913-934.

• Conference Proceedings (inc. Abstracts)

  • Greystoke A, Hogarth L, Patterson M, Williams I, Ness T, Georgiadis K, Bolt L, Bettison I, Turner D, Jamieson D, Simmons T, Hughes A, Jaedicke K, Gardiner J, Mulvenna P, Leaning D, Bradshaw A, Butler R, Black F. The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained. In: 14th Annual British Thoracic Oncology Group Conference 2016. 2016, Dublin, Ireland: Elsevier.
  • Wyatt N, Hogarth L, Turner D, Patterson M, Jamieson D, Black F, Hutton C, Mulvenna P, Simmons T, Bradshaw A, Kolenda C, Parker C, Martin-Ruiz C, Greystoke A. Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). In: IASLC 17th World Conference on Lung Cancer. 2016, Vienna, Austria: Elsevier.
  • Patterson MJ, Murray J, Curtin NJ. Stability of PARP Inhibition by BMN 673 in Human PBMCs (and Leukaemic Cell Cultures). In: 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2012, Dublin, Ireland: Pergamon.
  • Kaloriti D, Tillmann A, Jacobsen M, Yin Z, Patterson M, Radmaneshfar E, You T, Chandrasekaran K, Pang W, Coghill G, de Moura APS, Thiel M, Romano MC, Grebogi C, Haynes K, Quinn J, Gow NAR, Brown AJP. Impact of combinatorial stresses upon Candida albicans. In: 18th Congress of the International Society for Human and Animal Mycology. 2012, Berlin, Germany: Wiley-Blackwell Verlag GmbH.